CCR9 and Cowden disease: In a phase II trial for the treatment of moderate-to-severe CD (OPERA) clinical endpoints did not reach statistical significance in comparison to placebo (39, 40), but treatment led to a reduction of soluble MAdCAM-1 and to an increase of circulating β7+ central memory T cells and elevated CCR9 gene expression (41).